Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/148117
Title: CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons
Author: Calatayud Aristoy, Carles
Carola, Giulia
Fernandez-Carasa, Irene
Valtorta, Marco
Jiménez-Delgado, Senda
Díaz, Mònica
Soriano i Fradera, Jordi
Cappelletti, Graziella
García-Sancho, Javier
Raya Chamorro, Ángel
Consiglio, Antonella
Keywords: Malaltia de Parkinson
Ciències de la salut
Enginyeria genètica
Parkinson's disease
Medical sciences
Genetic engineering
Issue Date: 2-May-2019
Publisher: Nature Publishing Group
Abstract: Patient-specific induced pluripotent stem cells (iPSCs) are a powerful tool to investigate the molecular mechanisms underlying Parkinson's disease (PD), and might provide novel platforms for systematic drug screening. Several strategies have been developed to generate iPSC-derived tyrosine hydroxylase (TH)-positive dopaminergic neurons (DAn), the clinically relevant cell type in PD; however, they often result in mixed neuronal cultures containing only a small proportion of TH-positive DAn. To overcome this limitation, we used CRISPR/Cas9-based editing to generate a human iPSC line expressing a fluorescent protein (mOrange) knocked-in at the last exon of the TH locus. After differentiation of the TH-mOrange reporter iPSC line, we confirmed that mOrange expression faithfully mimicked endogenous TH expression in iPSC-derived DAn. We also employed calcium imaging techniques to determine the intrinsic functional differences between dopaminergic and non-dopaminergic ventral midbrain neurons. Crucially, the brightness of mOrange allowed direct visualization of TH-expressing cells in heterogeneous cultures, and enabled us to isolate live mOrange-positive cells through fluorescence-activated cell sorting, for further differentiation. This technique, coupled to refined imaging and data processing tools, could advance the investigation of PD pathogenesis and might offer a platform to test potential new therapeutics for PD and other neurodegenerative diseases.
Note: Reproducció del document publicat a: https://doi.org/10.1038/s41598-019-43080-2
It is part of: Scientific Reports, 2019, vol. 9, p. 6811
URI: http://hdl.handle.net/2445/148117
Related resource: https://doi.org/10.1038/s41598-019-43080-2
ISSN: 2045-2322
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Física de la Matèria Condensada)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
690555.pdf3.13 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons